Sana Biotechnology announced the funding of all tranches of its initial financing, raising over $700 million. With this financing, Sana’s shareholders include ARCH Venture Partners, Flagship Pioneering, Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, Alaska Permanent Fund, the Public Sector Pension Investment Board, Bezos Expeditions, GV, Omega Funds, Altitude Life Science Ventures, and multiple unnamed institutional investors. Sana Biotechnology officially launched in January of 2019.
Proceeds from Sana’s financing will be used to advance discovery and development within the company’s core platforms, including gene delivery, immunology, stem cell biology, and gene modification and control. Sana’s approaches include in vivo delivery of genetic payloads to specific cells, ex vivo genetic modifications that hide allogeneic cells from a patient’s immune system, and applying stem cell biology to make differentiated cells to replace missing or damaged tissue. Proceeds are expected to support IND-enabling and initial clinical studies for multiple therapeutic candidates, build-out manufacturing capabilities, and expansion of the company’s portfolio of enabling technologies. They will also support the continued addition of top talent to Sana’s team.